Premium
A novel acute lymphoid leukaemia type BCR/ABL transcript in chronic myelogenous leukaemia
Author(s) -
Okamoto Kiyoshi,
Karasawa Masamitsu,
Sakai Hirotaka,
Ogura Hidemi,
Morita Kimio,
Naruse Takuji
Publication year - 1997
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1997.d01-2066.x
Subject(s) - chronic myelogenous leukemia , exon , fusion transcript , breakpoint cluster region , biology , abl , microbiology and biotechnology , reverse transcription polymerase chain reaction , polymerase chain reaction , fusion gene , reverse transcriptase , cancer research , messenger rna , leukemia , genetics , gene , receptor , tyrosine kinase
Using a reverse transcription‐polymerase chain reaction (RT‐PCR), we identified a patient with typical clinical features of chronic myelogenous leukaemia (CML) in the chronic phase who showed no amplification of the CML‐type BCR/ABL transcript. RT‐PCR with primers detecting the acute lymphoid leukaemia (ALL)‐type transcript disclosed a novel fragment co‐amplified with an ALL‐type fragment. Sequencing revealed the novel transcript to be a chimaeric mRNA produced by fusion of a segment of BCR exon 2 (e2) to ABL exon 2 (a2), with a 21 base‐pair insertion of ABL intron 1b sequence between them. This transcript has not been reported previously.